Treatment of COPD with a minimally invasive investigative procedure called targeted lung denervation (TLD) is feasible, safe, and was found to improve lung function, according to researchers.

Their study, “Long-term safety of bilateral targeted lung denervation in patients with COPD,” was published in the International Journal of Chronic Obstructive Pulmonary Disease.

COPD treatment requires new approaches providing durable health improvements, despite the current availability of options such as bronchodilators or inhaled glucocorticosteroids.

However, the use of alternative options still requires the evaluation of long-term safety before the start of larger clinical trials.